Trial Profile
Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Conteltinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Centaurus Biopharma
- 31 Jan 2017 Status changed from not yet recruiting to recruiting.
- 08 Mar 2016 New trial record